Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Accounts Payables (2016 - 2025)

Sanofi's Accounts Payables history spans 8 years, with the latest figure at $8.6 billion for Q4 2025.

  • For Q4 2025, Accounts Payables rose 6.19% year-over-year to $8.6 billion; the TTM value through Dec 2025 reached $8.6 billion, up 6.19%, while the annual FY2025 figure was $8.3 billion, 1.76% up from the prior year.
  • Accounts Payables for Q4 2025 was $8.6 billion at Sanofi, up from $8.1 billion in the prior quarter.
  • Across five years, Accounts Payables topped out at $8.6 billion in Q4 2025 and bottomed at $7.0 billion in Q4 2022.
  • The 5-year median for Accounts Payables is $7.9 billion (2023), against an average of $7.7 billion.
  • The largest annual shift saw Accounts Payables dropped 1.68% in 2022 before it increased 13.43% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $7.1 billion in 2021, then dropped by 1.68% to $7.0 billion in 2022, then increased by 13.43% to $7.9 billion in 2023, then grew by 2.34% to $8.1 billion in 2024, then grew by 6.19% to $8.6 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Accounts Payables are $8.6 billion (Q4 2025), $8.1 billion (Q4 2024), and $7.9 billion (Q4 2023).